Medical network - March 20 children with hyperactivity syndrome is also called attention deficit hyperactivity disorder (ADHD), hereinafter referred to as attention deficit disorder, is a common childhood behavior disorders, clinical characteristic is intelligence is normal or near normal children, with age disproportionate attention and attention span, the excessive activity of mh, emotional impulsive accompanied by a group of syndrome that learning difficulties. With rapid development of economic and cultural situation in China, relates to the healthy growth of teenagers, were of Confucianism.
According to related research reports, foreign epidemiological investigation ADHD morbidity is 4-29% of the total population, 4.6% in Japan, South Korea is 12.1%. In December 2015, China promulgated the China of attention deficit hyperactivity disorder prevention guide second edition. Emphasis on attention deficit hyperactivity disorder (attention deficit hyperactive disorder, ADHD) is a neurodevelopmental disorder syndrome, the overall prevalence of about 5.7% of China's children's ADHD. This is part of the most common form of childhood behavior disorders, but lasting a lifetime even influence to this group. Treatment of first-line drug ritalin, mo paxil is income 2017 the catalog of national health care medicine. With the increase of human on health investment, drive the market growth of ADHD.
ADHD market abroad increased year by year
Drug PDB database according to the Chinese pharmaceutical industry information center, according to the 2016 global attention deficit hyperactivity disorder drug market has reached $7.264 billion, year-on-year growth of 8.85% a year, from growth curve chart shows steady growth. Its main varieties is drug ritalin hydrochloride series, lai right benzedrine, mo paxil, guanfacine, grace that card than gabapentin, into the global top 500 bestseller lists of ADHD drugs account for more than 60% of this class of drugs.
ADHD drugs TOP5 brand is Mr Vyvanse increase neurotransmitters (dimethyl sulfonate lai right benzedrine) in the first place, annual sales of $2016 and $2.007 billion, year-on-year growth of 16.55% a year, in 2016 entered the global top 100 best-selling drug list, is ranked at 55.
Dimethyl sulfonate lai right benzedrine oral capsule is November 15, 2010, approved by FDA Mr (Shire) company listed in the U.S. drug, is suitable for the treatment of 6 ~ 12 years old children's attention deficit/hyperactivity disorder. The mechanism of action of right benzedrine affect balance a variety of neurotransmitters in the brain, for the treatment of paroxysmal sleep disease, hyperactivity. At the same time can improve mental abnormality, stereotypia, cognitive deficiency syndrome.
Later in the United States in February 2012, the FDA approved its prescription drugs Vyvanse increase neurotransmitters in maintenance treatment for adult adhd. Announced on January 30, 2015, the FDA approved Vyvanse increase neurotransmitters (dimethyl sulfonate lai right benzedrine) of new, used in the treatment of overeating. Vyvanse increase neurotransmitters is first approved by the FDA for this indication of drugs, thus promote the market growth. Vyvanse increase neurotransmitters are classified as class II controlled medicines, the domestic development also has a certain threshold. At present domestic is not listed, send information and did not see the drug registration, should cause the attention of domestic research pipeline.
TOP5 brand in second place was Johnson &johnson methylphenidate hydrochloride, commodity name Concerta; Annual sales of $2016 and $862 million, year-on-year growth of 5.12% a year. Johnson & Johnson in 2001 for $10.5 billion after the acquisition of companies muntadhar al-zeidi Concerta are obtained. At present, the patent expired methylphenidate hydrochloride, a number of generic drugs, drugs become unique. In 2015, according to global ritalin hydrochloride series drug overall market up to 3.418 billion yuan. In addition, Johnson &johnson's Concerta has multiple common name.
In 2015 the FDA approved Pfizer's ritalin slow-release chewable tablet (Quilli Chew ER) for the treatment of more than 6 years old children's attention deficit hyperactivity disorder (ADHD), approved specifications have 20, 30 and 40 mg. This article recommended dose for 20 mg a day, day maximum dose not more than 60 mg.
And novartis Ritalin, Allergan company and malinkes Methylphenidate ER, Belgium optimal than Equasym XL/Metadate CD company, Japan's long light pharmaceutical Daytrana, Mr Company Equasym XL and Allergan (Allergan) Methylphenidate hydrochloride IMPAX laboratory in the United States. Including Johnson &johnson Concerta occupies 24% share of Methylphenidate hydrochloride, allergan company and malinkes Methylphenidate ER Methylphenidate hydrochloride 19.46% market share, novartis's Ritalin (Ritalin) accounted for 10.68%.
TOP5 brand in third place was lilly's hydrochloric acid using 3-phenyipropanol paxil, Strattera commodity name. Strattera generated sales of around $2016 in 855 million, year-on-year growth of 14.30% a year. TOP5 brand the other two drugs is novartis Ritalin and the treaty with Intuniv (guanfacine), foreign ADHD drugs market competition is intense.
Domestic ADHD drugs on the market
The China of attention deficit hyperactivity disorder prevention guide recommended drugs for central stimulant, central norepinephrine regulating drugs. Recommend ritalin and 3-phenyipropanol paxil as first-line drug treatment, ritalin, mo paxil are income in 2009 and 2009 of the catalog of national health care medicine drugs.
2016, samples of the key cities for the domestic hospital hydrochloride ritalin sales of 26.82 million yuan, a year-on-year growth of 10.23% a year. I have approved 4 listed ritalin hydrochloride. Imported drugs Janssen - Cilag of Limited company of hydrochloric acid ritalin zyban, commodity called focus of (Concerta); Domestic is the first one in suzhou pharmaceutical ritalin hydrochloride tablet and injection of huarun double crane pharmaceutical and tonghua RenMin drug ritalin hydrochloride.
ADHD drugs on the market at home, another drug is hydrochloric acid using 3-phenyipropanol paxil capsule, approved a total of three listed. LILLY has approved vendor is Spain S.A. company, brand name choose sida (Strattera); Domestic drug is topfond pharmaceutical and pharmaceutical production of hydrochloric acid is jiangsu dafeng sea 3-phenyipropanol paxil capsules. 2016 samples of the key cities for the domestic hospital 3-phenyipropanol hydrochloride was 19.2 million yuan, a year-on-year growth of 6.83% a year. Samples of the key cities for the overall analysis, the domestic hospitals ritalin hydrochloric acid and hydrochloric acid using 3-phenyipropanol paxil agents, mainly for foreign drug dominated, still need to increase the development of domestic drug market.
Children with hyperactivity syndrome also called attention deficit hyperactivity disorder (ADHD), hereinafter referred to as attention deficit disorder, is a common childhood behavior disorders, clinical characteristic is intelligence is normal or near normal children, with age disproportionate attention and attention span to narrow, the excessive activity of mh, emotional impulsive accompanied by a group of syndrome that learning difficulties. With rapid development of economic and cultural situation in China, relates to the healthy growth of teenagers, were of Confucianism.
According to related research reports, foreign epidemiological investigation ADHD morbidity is 4-29% of the total population, 4.6% in Japan, South Korea is 12.1%. In December 2015, China promulgated the China of attention deficit hyperactivity disorder prevention guide second edition. Emphasis on attention deficit hyperactivity disorder (attention deficit hyperactive disorder, ADHD) is a neurodevelopmental disorder syndrome, the overall prevalence of about 5.7% of China's children's ADHD. This is part of the most common form of childhood behavior disorders, but lasting a lifetime even influence to this group. Treatment of first-line drug ritalin, mo paxil is income 2017 the catalog of national health care medicine. With the increase of human on health investment, drive the market growth of ADHD.
ADHD market abroad increased year by year
Drug PDB database according to the Chinese pharmaceutical industry information center, according to the 2016 global attention deficit hyperactivity disorder drug market has reached $7.264 billion, year-on-year growth of 8.85% a year, from growth curve chart shows steady growth. Its main varieties is drug ritalin hydrochloride series, lai right benzedrine, mo paxil, guanfacine, grace that card than gabapentin, into the global top 500 bestseller lists of ADHD drugs account for more than 60% of this class of drugs.
ADHD drugs TOP5 brand is Mr Vyvanse increase neurotransmitters (dimethyl sulfonate lai right benzedrine) in the first place, annual sales of $2016 and $2.007 billion, year-on-year growth of 16.55% a year, in 2016 entered the global top 100 best-selling drug list, is ranked at 55.
Dimethyl sulfonate lai right benzedrine oral capsule is November 15, 2010, approved by FDA Mr (Shire) company listed in the U.S. drug, is suitable for the treatment of 6 ~ 12 years old children's attention deficit/hyperactivity disorder. The mechanism of action of right benzedrine affect balance a variety of neurotransmitters in the brain, for the treatment of paroxysmal sleep disease, hyperactivity. At the same time can improve mental abnormality, stereotypia, cognitive deficiency syndrome.
Later in the United States in February 2012, the FDA approved its prescription drugs Vyvanse increase neurotransmitters in maintenance treatment for adult adhd. Announced on January 30, 2015, the FDA approved Vyvanse increase neurotransmitters (dimethyl sulfonate lai right benzedrine) of new, used in the treatment of overeating. Vyvanse increase neurotransmitters is first approved by the FDA for this indication of drugs, thus promote the market growth. Vyvanse increase neurotransmitters are classified as class II controlled medicines, the domestic development also has a certain threshold. At present domestic is not listed, send information and did not see the drug registration, should cause the attention of domestic research pipeline.
TOP5 brand in second place was Johnson &johnson methylphenidate hydrochloride, commodity name Concerta; Annual sales of $2016 and $862 million, year-on-year growth of 5.12% a year. Johnson & Johnson in 2001 for $10.5 billion after the acquisition of companies muntadhar al-zeidi Concerta are obtained. At present, the patent expired methylphenidate hydrochloride, a number of generic drugs, drugs become unique. In 2015, according to global ritalin hydrochloride series drug overall market up to 3.418 billion yuan. In addition, Johnson &johnson's Concerta has multiple common name.
In 2015 the FDA approved Pfizer's ritalin slow-release chewable tablet (Quilli Chew ER) for the treatment of more than 6 years old children's attention deficit hyperactivity disorder (ADHD), approved specifications have 20, 30 and 40 mg. This article recommended dose for 20 mg a day, day maximum dose not more than 60 mg.
And novartis Ritalin, Allergan company and malinkes Methylphenidate ER, Belgium optimal than Equasym XL/Metadate CD company, Japan's long light pharmaceutical Daytrana, Mr Company Equasym XL and Allergan (Allergan) Methylphenidate hydrochloride IMPAX laboratory in the United States. Including Johnson &johnson Concerta occupies 24% share of Methylphenidate hydrochloride, allergan company and malinkes Methylphenidate ER Methylphenidate hydrochloride 19.46% market share, novartis's Ritalin (Ritalin) accounted for 10.68%.
TOP5 brand in third place was lilly's hydrochloric acid using 3-phenyipropanol paxil, Strattera commodity name. Strattera generated sales of around $2016 in 855 million, year-on-year growth of 14.30% a year. TOP5 brand the other two drugs is novartis Ritalin and the treaty with Intuniv (guanfacine), foreign ADHD drugs market competition is intense.
Domestic ADHD drugs on the market
The China of attention deficit hyperactivity disorder prevention guide recommended drugs for central stimulant, central norepinephrine regulating drugs. Recommend ritalin and 3-phenyipropanol paxil as first-line drug treatment, ritalin, mo paxil are income in 2009 and 2009 of the catalog of national health care medicine drugs.
2016, samples of the key cities for the domestic hospital hydrochloride ritalin sales of 26.82 million yuan, a year-on-year growth of 10.23% a year. I have approved 4 listed ritalin hydrochloride. Imported drugs Janssen - Cilag of Limited company of hydrochloric acid ritalin zyban, commodity called focus of (Concerta); Domestic is the first one in suzhou pharmaceutical ritalin hydrochloride tablet and injection of huarun double crane pharmaceutical and tonghua RenMin drug ritalin hydrochloride.
ADHD drugs on the market at home, another drug is hydrochloric acid using 3-phenyipropanol paxil capsule, approved a total of three listed. LILLY has approved vendor is Spain S.A. company, brand name choose sida (Strattera); Domestic drug is topfond pharmaceutical and pharmaceutical production of hydrochloric acid is jiangsu dafeng sea 3-phenyipropanol paxil capsules. 2016 samples of the key cities for the domestic hospital 3-phenyipropanol hydrochloride was 19.2 million yuan, a year-on-year growth of 6.83% a year. Samples of the key cities for the overall analysis, the domestic hospitals ritalin hydrochloric acid and hydrochloric acid using 3-phenyipropanol paxil agents, mainly for foreign drug dominated, still need to increase the development of domestic drug market. |
